Monoclonal Antibodies Market, By source (Murine, Chimeric, Humanized and Human), by diseases (Autoimmune diseases, Inflammatory diseases, Infectious diseases and others), by end user (hospitals, research labs and others) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025

Publisher Name: Analyst View Market Insights
No. of Pages: 68
Publication Month:
Jul-17

REPORT HIGHLIGHT
The monoclonal antibody market is estimated to represent a global market of USD 135.6 billion by 2025 with growth rate of 4.8%. Biologics industry has been constantly on rise which strongly support the growth of monoclonal antibody market. Due to this fact, the utilization of monoclonal antibody has increased over the past few years owing to the increased awareness of these therapeutics among physicians and patients.For example, in 2012, approximately 20% of the total pharmaceutical revenue generated from biologic products and is anticipated to increase around 25% by the end of 2018.
Furthermore, successful commercialization of monoclonal antibodies like Avastin, Rituxan and Remicade further boosted the customer base. For example, mAbs such as Avastin clocked more than US$ 6 billion of sale across the globe in 2013. Increasing uptake of these therapeutics support the market development.
The market covers the analysis of the commercial or pipeline monoclonal antibody therapeutics such as Humira (adalimumab, anti-TNF), Enbrel, Remicade, Rituxan, Avastin, Herceptin, Lucentis, Erbitux, Eylea and many others.The global market is categorized in terms of source, end use and diseases. Based on source, the market is divided in murine, chimeric, humanized and human. Humanized and human segments are accounted for the largest share of the global market. Reason behind the high growth of this segments as these are considered as a natural drug and offers good safety on in vivo use.Synagis, Herceptin, Zenapax, Myelotarg, Campath, Xolair, Raptiva, Avastin, Tsyabri, Humira, Vectibix , and Cosentyx are some of the examples of human or humanized monoclonal antibodies.
In terms of diseases, the market is segmented as autoimmune diseases, Inflammatory diseases, Infectious diseases and others. The utilization of monoclonal antibody therapeutics in cancer treatments and autoimmune diseases is whooping the market growth. Continuous rise in the incidence rate of cancer and autoimmune diseases along with growing demand for effective therapeutics in these area drive the market growth to great extent. End user segment is divided as hospitals, research laboratories and others. Hospitals segment dominated the market, captured almost 41.23% share of the global market in 2016.

Regionally, developed regions such as North America and Europe are considered to be the largest market. Of which, North America accounted for almost 50% share of the global market in 2016. Increasing number of research and development activities coupled with rise in awareness among end users about monoclonal antibody drives the market growth. U.S. based Pfizer, Inc. is currently researching on avelumab—monoclonal antibody for indications such as non-small cell lung cancer, ovarian cancer, and others. These companies spenda significant share of their revenue on research activities, to develop novel mAbs.
Europe is also considered to capture significant market share, 25% global share in 2016. Increasing approval of novel monoclonal antibodies is expected to stimulate the market demand. In 2012, European Medicines Agency (EMA) released guidelines on biosimilar mAb development. This guideline demonstrates the capability of biosimilar mAbs with an interest in development of similar biological mAbs, leading to drive market growth. Asia Pacific and Latin American countries are projected to grow with the promising growth rate during the future period.
Companies such as F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc, Novartis AG; Pfizer; Shanghai Junshi Bioscience Co., Ltd, Daiichi Sankyo Company, Ltd., and others are operating in this market. These companies are engaged in strategic merger and acquisitions to expand their market share in this market. For example, Roche, Inc. acquired California based Genentech which has helped company to expand its market share in monoclonal antibody segment. Aside from Roche, Abbott Laboratories also exhibit strong potential in the monoclonal antibody sector. Growth of this company is attributed to its acquisition of Knoll Pharmaceutical Co. unit and licensing rights to MedImmune’s Synagis and Numax. Further, Johnson & Johnson enhance its market presence supported by the strong growth of Stelara (ustekinumab), Simponi (golimumab), and bapineuzumab.
The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment.
The years considered for the study are:
Historical Year – 2014 & 2015
Base Year – 2015
Estimated Year – 2016
Projected Year – 2025
TARGET AUDIENCE
Traders, Distributors, And Suppliers
Hospitals
Manufacturers
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY SOURCE
Murine
Chimeric
Humanized
Human
MARKET, BY DISEASE
Autoimmune diseases
Inflammatory diseases
Infectious diseases
others
MARKET, BY END USE
Hospitals
Research labs
Others
MARKET, BY REGION
North America
Europe
Asia Pacific
Rest of the World
MARKET, BY COUNTRY
Further Breakdown of The North America Market
U.S.
Canada
Further Breakdown of The Europe Market
Germany
France
Rest of Europe
Further Breakdown of The APAC Market
India
China
Rest of APAC
Further Breakdown of The Rest of the World Market
Middle-East and Africa
Latin America

TABLE OF CONTENTS
MONOCLONAL ANTIBODIES MARKET OVERVIEW
Study Scope
Base Year
Assumption and Methodology
EXECUTIVE SUMMARY
Key Market Facts
Geographical Scenario
Companies in the Market
MONOCLONAL ANTIBODIES KEY MARKET TRENDS
Market Drivers
Impact Analysis of Market Drivers
Market Restraints
Impact Analysis of Market Restraints
Market Opportunities
Market Future Trends
MONOCLONAL ANTIBODIES INDUSTRY STUDY
Company Activity Analysis
Regulatory Framework Analysis
Pipeline Analysis
Value Chain Analysis
MONOCLONAL ANTIBODIES MARKET LANDSCAPE
Market Share Analysis
Key Innovators
MONOCLONAL ANTIBODIES MARKET – BY SOURCE:
Overview
Murine
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Chimeric
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Humanized
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Human
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
MONOCLONAL ANTIBODIES MARKET – BY DISEASE:
Overview
Autoimmune Disease
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Inflammatory Disease
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Infectious Disease
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Others
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
MONOCLONAL ANTIBODIES MARKET – BY END USE:
Overview
Hospitals
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Research Labs
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Others
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
MONOCLONAL ANTIBODIES MARKET– BY GEOGRAPHY
Introduction
North America
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
S.
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Canada
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Europe
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
France
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Germany
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Rest of Europe
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Asia Pacific (APAC)
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
China
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
India
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Rest of APAC
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Rest of the World
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Latin America
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Middle East and Africa
Overview
Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
KEY VENDOR ANALYSIS
Hoffmann-La Roche Ltd
Company Overview
SWOT Analysis
Key Developments
GlaxoSmithKline plc
Company Overview
SWOT Analysis
Key Developments
Novartis AG
Company Overview
SWOT Analysis
Key Developments
Pfizer, Inc.
Company Overview
SWOT Analysis
Key Developments
Shanghai Junshi Bioscience Co., Ltd,
Company Overview
SWOT Analysis
Key Developments
Daiichi Sankyo Company, Ltd.
Company Overview
SWOT Analysis
Key Developments
Bristol-Myers Squibb Company
Company Overview
SWOT Analysis
Key Developments
Elan
Company Overview
SWOT Analysis
Key Developments
360 DEGREE ANALYSTVIEW
APPENDIX
Research Methodology
Abbreviations
Disclaimer
Contact Us

SCOPE AND OBJECTIVES
The objective of this report is to describe the market trends and revenue forecasts for the monoclonal antibody market for the upcoming years. The report focuses on defining and describing the key influencing factors for the growth of the market. It also offers an in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, key market players, and premium industry trends.
The report tracks the major market events including product launches, technological developments, mergers & acquisitions, and the innovative business strategies opted by key market players. Along with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities and challenges in the coil coatings market. The scope of this report covers the genitourinary drugs Market by its major segments, which include the source, disease end user industry, and the major geographic regions.
KEY BENEFITS OF THE REPORT:
Understanding of the strategies that are being adopted by the key players in this market to stay competitive
Extensive analysis of the key players dominating the competitive landscape of this market
In-depth analysis of the key factors are propelling the growth of the global market
Detailed analysis of the geographic region that will witness the strongest growth
Granular analysis of the current market scenario and the expected market grow

Enterprise User Licence Price (USD)Single User Licence Price (USD)
Clear